Evidence map›Paper›PMID 31037122›Full record

ArticleTheranostics2019

Anti-tumor effects and potential therapeutic response biomarkers in α-emitting

Yasuhiro Ohshima, Nobuaki Kono, Yuichiro Yokota, Shigeki Watanabe, Ichiro Sasaki, Noriko S Ishioka, Tetsuya Sakashita, Kazuharu Arakawa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Production ofEJNMMI radiopharmacy and chemistry · 2025
    Article
  3. Review
  4. Recent advances in the development ofAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Review
  5. Review
  6. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yasuhiro OhshimaDepartment of Radiation-Applied Biology Research, Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.
Nobuaki KonoInstitute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, 997-0052, Japan.
Yuichiro YokotaDepartment of Radiation-Applied Biology Research, Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.
Shigeki WatanabeDepartment of Radiation-Applied Biology Research, Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.
Ichiro SasakiDepartment of Radiation-Applied Biology Research, Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.
Noriko S IshiokaDepartment of Radiation-Applied Biology Research, Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.
Tetsuya SakashitaDepartment of Radiation-Applied Biology Research, Quantum Beam Science Research Directorate, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan.
Kazuharu ArakawaInstitute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, 997-0052, Japan.
Keio University · JPKeio University Shonan Fujisawa · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted α-particle therapy is a promising option for patients with malignant pheochromocytoma. Recent observations regarding

Indexed as

Adrenal Gland NeoplasmsAlpha ParticlesAnimalsBiomarkers, TumorGene Expression ProfilingGuanidinesPC12 CellsPheochromocytomaRatsTranscriptome1-(3-astatobenzyl)guanidineBiomarkers, TumorGuanidinesmeta-211At-astato-benzylguanidinePET imagingpheochromocytomaradionuclide therapyRNA-sequencingα-particle

Identifiers

PMID31037122
PMCPMC6485192
OpenAlexW2923497234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.